Scarica l'app Stockscreener
4.06
0.98%
-0.04
Dopo l'orario di chiusura:
4.06
Orchestra Biomed Holdings Inc Borsa (OBIO) Ultime notizie
OBIO Q1 2026 Earnings: Narrowed Loss as EPS Surpasses Estimates; Stock Posts Modest DeclineHot Market Picks - Newser
Orchestra BioMed Advances FDA Path for Hypertension Device - MyChesCo
Orchestra BioMed Targets 2027 Data for Hypertension Trial - MyChesCo
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
Orchestra BioMed director Jason buys $2,493 in stock - Investing.com UK
Orchestra BioMed director Jason buys $2,493 in stock By Investing.com - Investing.com Canada
Orchestra BioMed (OBIO) director adds 665 shares in open-market buy - Stock Titan
Orchestra BioMed Holdings (OBIO) price target increased by 11.30% to 12.68 - MSN
Orchestra BioMed CEO David Hochman buys $18,850 in company stock By Investing.com - Investing.com Nigeria
Orchestra BioMed director Aryeh Jason buys $34,986 in stock By Investing.com - Investing.com Nigeria
Orchestra BioMed CEO David Hochman buys $18,850 in company stock - Investing.com India
Jefferies healthcare fireside chat to feature Orchestra BioMed CEO - Stock Titan
Director at Orchestra BioMed (OBIO) buys 8,971 shares in open market - Stock Titan
Orchestra BioMed (OBIO) director adds 5,000 shares in open-market buy - Stock Titan
B. Riley Cuts Price Target on Orchestra BioMed Holdings to $10 From $12, Keeps Buy Rating - marketscreener.com
Orchestra BioMed director Fain buys $82,600 in shares By Investing.com - Investing.com South Africa
Orchestra BioMed director Fain buys $82,600 in shares - Investing.com UK
Orchestra BioMed (OBIO) director trust buys 20,000 shares - Stock Titan
Orchestra BioMed Holdings, Inc. (OBIO) reports Q1 loss, lags revenue estimates - MSN
Orchestra BioMed Secures Ligand Funding for Pivotal Trials - MyChesCo
H.C. Wainwright Maintains Orchestra BioMed(OBIO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Orchestra BioMed Secures Medtronic Funding for Hypertension Trial - MyChesCo
Orchestra BioMed Holdings (OBIO) Receives a Buy from H.C. Wainwright - The Globe and Mail
OBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Orchestra BioMed Holdings, Inc. Stock 12‑Month Price Target Raised to $12.57, Implies 210% Upside - TradingView
Orchestra BioMed Q1 Loss Narrows, Revenue Falls - Moomoo
TradingKey - TradingKey
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - Investing News Network
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Orchestra BioMed Holdings, Inc._March 31, 2026 - SEC.gov
Press Release: Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - Moomoo
Orchestra BioMed (NASDAQ: OBIO) Q1 2026 loss, cash and funding update - Stock Titan
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 - Investing News Network
Orchestra BioMed targets Q3 2026 enrollment for hypertension trial By Investing.com - Investing.com Australia
Orchestra BioMed targets Q3 2026 enrollment for hypertension trial - Investing.com
Orchestra Biomed Holdings Announces Update on Backbeat Global Pivotal Trial Timeline - marketscreener.com
Why Orchestra (OBIO) might be the best kept secret in the market (Grinds Higher) 2026-05-08Stock Idea Sharing Hub - newser.com
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):